Moreover, NAT2 590GA and AA presence was of no significant difference between diagnosed CML patients and the control (OR = 0.687, 95% CI: 0.389-2.1.211, p = 0. Here, NAT2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.